Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by USS Investment Management Ltd

USS Investment Management Ltd increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 241.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 117,922 shares of the biopharmaceutical company’s stock after buying an additional 83,430 shares during the quarter. USS Investment Management Ltd owned 0.09% of Alnylam Pharmaceuticals worth $29,117,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth about $278,321,000. Bank of New York Mellon Corp bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $148,128,000. Canada Pension Plan Investment Board bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $100,618,000. Korea Investment CORP acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $74,553,000. Finally, Pictet Asset Management Holding SA grew its position in shares of Alnylam Pharmaceuticals by 77.7% in the 3rd quarter. Pictet Asset Management Holding SA now owns 495,168 shares of the biopharmaceutical company’s stock valued at $122,783,000 after purchasing an additional 216,555 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have commented on the stock. Citigroup dropped their target price on shares of Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. HC Wainwright reduced their price target on shares of Alnylam Pharmaceuticals from $455.00 to $250.00 and set a “buy” rating for the company in a report on Tuesday. TD Cowen lowered their price objective on shares of Alnylam Pharmaceuticals from $482.00 to $354.00 and set a “buy” rating for the company in a research report on Friday, October 30th. JPMorgan Chase & Co. set a $254.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday. Finally, Bank of America reaffirmed a “buy” rating and issued a $287.00 price objective (down from $460.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.57.

Check Out Our Latest Analysis on ALNY

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. The trade was a 12.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Key Stories Impacting Alnylam Pharmaceuticals

Investors following ALNY have been watching these stories:

Alnylam Pharmaceuticals Trading Down 1.1%

Alnylam Pharmaceuticals stock opened at $147.82 on Friday. The company has a market cap of $19.80 billion, a price-to-earnings ratio of 7.67 and a beta of 0.42. The firm has a 50-day moving average of $210.88 and a 200-day moving average of $272.20. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43. Alnylam Pharmaceuticals, Inc. has a one year low of $146.51 and a one year high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 155.33% and a net margin of 52.85%. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the previous year, the business earned $2.90 earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.85 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

(Free Report)

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

Featured Stories

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.